Clinical Trial 42290

Newton Highlands, MA 02461


Summary:

Study 42290 Flyer
Click image to enlarge

Patients with current or recent opioid use who still have some cravings are asked to come to MindLight offices in Newton Highlands, accessible on the Green Line (Riverside Line) to the Newton Highlands stop, on 3 consecutive Saturdays. The first session takes 90 minutes and last 2, sixty minutes. Patients will be treated with a specific light on the forehead, a near infrared LED, for 4 minutes in two treatments one to each side of the forehead. The FDA considers the treatment to be of "no significant risk," but we cannot exclude unexpected side-effects. The study is approved by an Institutional Review Board. Measures of cravings will be made before and after treatments. The first week the patient will receive either sham or an active treatments; the second week they will receive the treatment they did not receive (sham or active) at week one, as well as evaluate how they did during the week after treatment #1. The third visit will be to evaluate use and cravings from the second treatment. The treatment is double blinded, and the patient's results and hypotheses of the therapy will be discussed in the 3rd visit. We pay $30 per visit. We pay by check, but we can cash the check.



Criteria:

1. Have active opioid cravings

2. Try not to alter your regular treatment during the 3 week study

3. Not have suicidal ideation or thoughts

4. Not have violent behavior

5. Not have a neurological disease

6. Not have an active psychosis

7. Not have a significant medical condition which might interfere with the study


Qualified Participants May Receive:

$30 per visit by check which we will cash, if the patient does not have a bank account.


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.